Pre-market hot trades in US stocks: authID pre-market down 7.67%; Coherent Corp. pre-market up 3.02%
I'm LongbridgeAI, I can summarize articles.authID pre-market down 7.67%; Coherent Corp. pre-market up 3.02%; RF Acquisition Corp II pre-market up 371.33%; Werewolf Therapeutics pre-market up 126.18%; RF ACQUISITION CORP II COM USD0.0001(S/R 15/02/2027) pre-market up 82.73%
Pre-market Hot Trades in US Stocks
authID fell 7.67% in pre-market trading, with no significant news recently. Trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.
Coherent Corp. rose 3.02% in pre-market trading. Based on recent key news:
-
On August 19, the expansion of AI data centers drove demand for optical transceiver modules, and Coherent's second-quarter financial report exceeded expectations, leading to a rise in stock price. Source: Zhitong Finance
-
On August 20, Coherent revealed an expanding outlook for the optical circuit switching market, with increased demand for CPO and NPO, and the market holds an optimistic view on its future growth. Source: Wall Street Insight
-
On August 18, Coherent began providing new silicon carbide substrate samples to AI chip manufacturers, enhancing heat dissipation performance, which positively impacted the stock price. Source: Dongfang Caifu Network. The demand in the optical communication industry is strong, driven by AI growth.
Top Gainers in Pre-market US Stocks
RF Acquisition Corp II rose 371.33% in pre-market trading. Based on recent key news:
-
On August 19, shareholders of RF Acquisition Corp II approved the business merger plan with Nanyang Bio. The advancement of this transaction significantly boosted the company's stock price, with The9 expected to hold 15% to 16% of the merged company.
-
On August 20, RF Acquisition Corp II released relevant announcements through the EDGAR system, further confirming the progress of the merger plan, enhancing market confidence and driving the stock price up.
-
On August 21, investors submitted preliminary redemption requests for 3.95 million shares. Although the final redemption numbers have not been confirmed, this dynamic shows the market's attention to the company's future development. The market has shown strong interest in the merger transaction, driving the stock price up significantly.
Werewolf Therapeutics rose 126.18% in pre-market trading. Based on recent key news:
-
On August 21, Werewolf Therapeutics announced a merger with Ambros Therapeutics, leading to a surge in stock price. Post-merger, the company will focus on developing the drug neridronate for treating CRPS-1, which has received FDA breakthrough therapy, fast track, and orphan drug designations, with the merger expected to be completed in the first quarter of 2027. This news pushed the stock price up by 141%. Source: Reuters
-
On August 20, Werewolf Therapeutics sold its inducer and Indukine platform to EMD Serono, receiving a $28 million upfront payment. This transaction provided additional funding support for the company, enhancing market confidence. Source: SEC announcement
-
On August 21, the company secured $150 million in new financing to support operations and clinical trials until early 2029. This financing further strengthens the company's financial position and boosts investor confidence. Source: GlobeNewswire. Recent financing activities in the biotechnology industry have been frequent, attracting high market attention.
RF ACQUISITION CORP II COM USD0.0001 (S/R 15/02/2027) pre-market rose 82.73%, with no significant news recently. Trading is active, and capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation